Featured in Business Insider: St. Louis’ API Innovation Center Leads the Way in Tackling Drug Supply Fragility

• April 23, 2026

Key takeaways: 

• The API Innovation Center released its 2026 white paper, “From Fragility to Resilience: Aligning Investment and Purchasing to Secure America’s Drug Supply Chain,” outlining a policy roadmap to secure the domestic generic drug supply chain.
• The white paper introduced the National Fragility Index (NFI), a first-of-its-kind framework designed to measure and identify vulnerabilities across the drug supply chain. 
• This work aligns with a broader trend across Missouri, where a strong and rapidly growing life sciences sector continues to gain national attention.

In a healthcare system increasingly strained by drug shortages, API Innovation Center (APIIC) in St. Louis is stepping forward with solutions that could reshape the future of pharmaceutical manufacturing in the United States.

APIIC’s newly released white paper, From Fragility to Resilience: Aligning Investment and Purchasing to Secure America’s Drug Supply Chain, underscores the critical reality that today’s drug shortages are symptoms of a deeply fragile supply chain. With more than 200 prescription medications currently in shortage nationwide, the need for a more resilient, domestically anchored system has never been clearer.

A key highlight of the report is APIIC’s introduction of the National Fragility Index (NFI), a first-of-its-kind framework designed to measure and identify vulnerabilities across the drug supply chain. By bringing data-driven insights into purchasing decisions, the NFI aims to shift the industry from reactive crisis management to proactive resilience planning.

According to Business Insider, “As policymakers, industry leaders and academic stakeholders continue to examine strategies for strengthening domestic generic pharmaceutical manufacturing, APIIC’s white paper provides a structured framework for moving from reactive responses to shortages toward a proactive approach to supply chain resilience.”

APIIC’s model of bringing together government, industry, and academia reflects Missouri’s collaboration as a defining advantage and a key to the state’s life sciences momentum.

This work aligns with a broader trend across Missouri, where a strong and rapidly growing life sciences sector continues to gain national attention. From cutting-edge research to scalable manufacturing, Missouri has built an ecosystem that supports innovation at every stage, making it an ideal location for companies focused on pharmaceutical production and supply chain security.

Read the full article in Business Insider.